Prior Authorization Form



Note: Please provide as much information as possible on this form. Missing data may cause processing delays for requested authorization(s). Attach additional sheets to this form if necessary.

Please fax the completed PA form and any additional informational sheets to Nirvanahealth at the following fax number: +1(866) 871-8565

Patient Information		Prescriber Information	
Patient Name:		Prescriber Name:	
Health Plan Name:		Prescriber Address:	
Patient Insurance Id:			
Patient Date of Birth:		Prescriber Phone: ()
Patient Phone:		Prescriber Fax: ()
_		Prescriber Specialty:	<u>`</u>
		Prescriber DEA:	
		Prescriber NPI:	
Medica	tion & Me	dical Information	
Requested Drug(s) & Strength(s):	[] Iclusia 1		olet [] Iclusig 30 mg tablet [] Iclusig
Requested Daily Quantity Limit – Amount:			
Requested Daily Quantity Limit – Days:			
Expected Length of Therapy:			
Directions:			
Diagnosis and Diagnosis Codes (ICD-10 Standard Codes):			
List drugs used previously to treat the same condition:			
Additional clinical information or history. Please include any relevant test results and/or medical record notes:			
	Questio	onnaire	
Q1: I, as the provider or designated representative of and accurate and that, upon request, I shall provide a necessary to verify my responses. (Check only one that	the provider	, certify and attest that the in	
[] Yes			
[] No			
Q2: Is the member currently treated with this medica	tion? (Check	only one that apply)	
[] Yes (please list start date of therapy (month/c (*Required)	lay/year))		
[] No			
Q3: What is the member's diagnosis? (Check only one	that apply)		

Prior Authorization Form



[] Chronic Myelogenous Leukemia
[] Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)
[] Other (please specify the member's diagnosis and provide clinical rationale for the request)(*Required)
Q4: What is the member's diagnosis? (Check only one that apply)
[] Chronic Myelogenous Leukemia (CML)
[] Philadelphia chromosome-positive Acute Lymphoblastic Leukemia (Ph+ ALL)
[] Other (please specify the member's diagnosis and provide clinical rationale for the request)(*Required)
Q5: Has the member had an inadequate response, intolerance or experienced contraindication(s) to at least two other tyrosine kinase inhibitors (e.g., Gleevec [imatinib], Sprycel, Tasigna, and Bosulif)? (Check only one that apply)
[] Yes (please specify drug name(s), corresponding contraindication(s) or intolerance experienced and the start and end da (s) of therapy (month/year))(*Required)
[] No (please provide clinical rationale for the request)(*Required)
Q6: Has the member had an inadequate response, intolerance or experienced contraindication(s) to at least two other FDA-approved tyrosine kinase inhibitors (e.g., Gleevec [imatinib], Sprycel)? (Check only one that apply)
[] Yes (please specify drug name(s), corresponding contraindication(s) or intolerance experienced and the start and end da (s) of therapy (month/year))
[] No (please provide clinical rationale for the request)(*Required)
Q7: Does the member have T315I mutation? (Check only one that apply)
[] Yes(*Required)
[] No (please provide clinical rationale for the request)(*Required)
Q8: Is the requested medication prescribed by or in consultation with an oncologist or hematologist? (Check only one that apply
[] Yes (please specify prescriber specialty)(*Required)
[] No (please provide clinical rationale for the request)(*Required)
<u>Attestation:</u> I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, Insurer, Medical Group or its designated representatives may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.
Signature of Prescriber or Authorized Representative: Date:
Print Authorized Representative Name: